[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
Jönsson
Linus
L
Neurotec, Karolinska Institutet, Stockholm Health Economics, Centre for Health Economics, Stockholm School of Economics, Stockholm. linus.j@healtheconomics.se
Borgström
Fredrik
F
Zethraeus
Niklas
N
D000368:Aged; D019386:Alendronate / Q000191:economics / Q000627:therapeutic use*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003718:Denmark; D016527:Drug Costs; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D018803:Models, Economic; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic
D019386:Alendronate